FDA approves Alzheimer’s disease drug donanemab
On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.
Shaping a future free from Alzheimer's disease
On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.
Wisconsin Alzheimer’s Institute staff and leaders helped lead development of state plan
DICE stands for Describe, Investigate, Create, Evaluate; a process for caregivers to identify underlying reasons for behaviors in a person with dementia and methods to address them, often without medications.
The researchers examined pathological data from 3,297 brain donors and biomarkers and clinical data from over 10,000 people, including participants from the Wisconsin Registry for Alzheimer’s Prevention and five large multicenter cohorts in Europe and the US.
The 10th annual Minority Health Month event drew a crowd of more than 300 attendees, bringing together community members for an entertaining play showing how one family responds when their beloved mother is diagnosed with Alzheimer’s disease. During the intermission of the performance, a panel of speakers discussed their experiences as caregivers to a person living with Alzheimer’s disease and dementia.
As the University of Wisconsin–Madison commemorated its 175th anniversary, an extra special melody of community and hope echoed through the campus halls, courtesy of The Amazing Grace Chorus®. The chorus, a community outreach program hosted by the Wisconsin Alzheimer’s Institute Regional Milwaukee Office, features people living with Alzheimer’s disease or related dementia and family caregivers. …
Maria Mora Pinzon, MD, MS, was interviewed on Telemundo Wisconsin in recent news segments. The appearances are part of monthly news interviews Mora Pinzon does with the news station on a variety of public health topics. Mora Pinzon stated that the cancers that most frequently affect men are prostate, colorectal and lung cancer. Prostate cancer …
UW–Madison Alzheimer’s disease research programs are a central part of work in the development of effective, accessible tools for Alzheimer’s disease blood detection.
The Wisconsin Alzheimer’s Institute’s Regional Milwaukee Office and its research programs are featured in a segment broadcast on Spectrum News 1. The news report interviews a participant enrolled in African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study and describes the health disparities in Alzheimer’s disease. AA-FAIM is a sub-study of the Wisconsin Registry for Alzheimer’s …
The funding is the largest NIH grant in university history